Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Current Liabilities: 2013-2024

Historic Total Current Liabilities for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $71.4 million.

  • Fortress Biotech's Total Current Liabilities fell 23.10% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year decrease of 23.10%. This contributed to the annual value of $71.4 million for FY2024, which is 15.91% down from last year.
  • Fortress Biotech's Total Current Liabilities amounted to $71.4 million in FY2024, which was down 15.91% from $84.9 million recorded in FY2023.
  • Over the past 5 years, Fortress Biotech's Total Current Liabilities peaked at $127.7 million during FY2022, and registered a low of $51.8 million during FY2020.
  • In the last 3 years, Fortress Biotech's Total Current Liabilities had a median value of $84.9 million in 2023 and averaged $94.7 million.
  • Per our database at Business Quant, Fortress Biotech's Total Current Liabilities skyrocketed by 95.21% in 2021 and then slumped by 33.52% in 2023.
  • Fortress Biotech's Total Current Liabilities (Yearly) stood at $51.8 million in 2020, then skyrocketed by 95.21% to $101.0 million in 2021, then climbed by 26.40% to $127.7 million in 2022, then plummeted by 33.52% to $84.9 million in 2023, then declined by 15.91% to $71.4 million in 2024.